Literature DB >> 22836311

Extracellular volume fractions in chronic myocardial infarction.

Kerstin Ulrike Bauner1, Andreas Biffar, Daniel Theisen, Andreas Greiser, Christoph Johannes Zech, Elsie T Nguyen, Maximilian F Reiser, Bernd J Wintersperger.   

Abstract

OBJECTIVES: The aim of this study was to assess and delineate chronic myocardial infarction (CMI) using precontrast and postcontrast T1 mapping techniques including quantification of extracellular volume fractions (ECVs).
MATERIALS AND METHODS: A total of 26 patients with CMI were examined at 1.5 T applying a modified Look-Locker Inversion Recovery sequence before and 10 minutes after contrast at 3 short-axis slice positions. An inversion recovery gradient recalled echo sequence (standard of reference) was used for imaging late gadolinium enhancement. Precontrast and postcontrast T1 maps were calculated, and CMI was defined as areas with T1 values more than 3 SDs different compared with normal myocardium (MYO). T1 values of CMI, MYO, and blood pool were measured, and ECVs of CMI and MYO were calculated. Two-tailed Student t test was used for statistical analysis of T1 values and ECVs. Sensitivities and specificities for detection of CMI on precontrast and postcontrast T1 maps were calculated. Receiver operating characteristic (ROC) analysis was performed for postcontrast T1 values and ECV for discrimination of CMI.
RESULTS: The comparison of T1 values of CMI and MYO revealed significant differences in precontrast and postcontrast scans (1159 ± 64 vs 1001 ± 47 milliseconds, P < 0.001, and 238 ± 74 vs 379 ± 59 milliseconds, P < 0.001). Sensitivities and specificities for detection of CMI on T1 mapping were 41.7% and 100% in precontrast Look-Locker Inversion Recovery scans and 95.8% and 99.3% in postcontrast images, respectively. Average ECV for MYO and CMI were 28% ± 5% and 53% ± 10% (P < 0.001). ROC analysis revealed nonsignificantly different areas under the curve of 0.937 and 0.997 for T1 values and ECV, respectively (P = 0.137). Sensitivities and specificities were 92.3% and 92.3% for detecting CMI by postcontrast T1 values and 95.5% and 100% for ECV, with cutoff values being 305 milliseconds or less and greater than 42%. Combined criteria did not result in any further improvement of sensitivity for CMI detection.
CONCLUSIONS: Postcontrast T1 values and ECV of chronically infarcted MYO are significantly different compared with respective values of normal MYO. Both parameters allow for accurate detection of CMI with ECV showing marginally higher sensitivity and specificity. Precontrast T1 values lack accuracy in delineation of CMI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836311     DOI: 10.1097/RLI.0b013e3182631c37

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  14 in total

1.  Determination of location, size, and transmurality of chronic myocardial infarction without exogenous contrast media by using cardiac magnetic resonance imaging at 3 T.

Authors:  Avinash Kali; Ivan Cokic; Richard L Q Tang; Hsin-Jung Yang; Behzad Sharif; Eduardo Marbán; Debiao Li; Daniel S Berman; Rohan Dharmakumar
Journal:  Circ Cardiovasc Imaging       Date:  2014-03-28       Impact factor: 7.792

Review 2.  Tissue characterization of the myocardium: state of the art characterization by magnetic resonance and computed tomography imaging.

Authors:  Puskar Pattanayak; David A Bleumke
Journal:  Radiol Clin North Am       Date:  2014-12-18       Impact factor: 2.303

3.  Non-contrast myocardial infarct scar assessment using a hybrid native T1 and magnetization transfer imaging sequence at 1.5T.

Authors:  Chong Duan; Yanjie Zhu; Jihye Jang; Jennifer Rodriguez; Ulf Neisius; Ahmed S Fahmy; Reza Nezafat
Journal:  Magn Reson Med       Date:  2018-12-18       Impact factor: 4.668

4.  Point estimate and reference normality interval of MRI-derived myocardial extracellular volume in healthy subjects: a systematic review and meta-analysis.

Authors:  Francesco Sardanelli; Simone Schiaffino; Moreno Zanardo; Francesco Secchi; Paola Maria Cannaò; Federico Ambrogi; Giovanni Di Leo
Journal:  Eur Radiol       Date:  2019-05-02       Impact factor: 5.315

5.  Myocardial T1 mapping: techniques and potential applications.

Authors:  Jeremy R Burt; Stefan L Zimmerman; Ihab R Kamel; Marc Halushka; David A Bluemke
Journal:  Radiographics       Date:  2014 Mar-Apr       Impact factor: 5.333

Review 6.  Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail.

Authors:  Summer Hassan; Carolyn J Barrett; David J Crossman
Journal:  Biophys Rev       Date:  2020-07-23

7.  In vivo contrast free chronic myocardial infarction characterization using diffusion-weighted cardiovascular magnetic resonance.

Authors:  Christopher Nguyen; Zhaoyang Fan; Yibin Xie; James Dawkins; Eleni Tseliou; Xiaoming Bi; Behzad Sharif; Rohan Dharmakumar; Eduardo Marbán; Debiao Li
Journal:  J Cardiovasc Magn Reson       Date:  2014-09-17       Impact factor: 5.364

Review 8.  Myocardial T1 and T2 Mapping: Techniques and Clinical Applications.

Authors:  Pan Ki Kim; Yoo Jin Hong; Dong Jin Im; Young Joo Suh; Chul Hwan Park; Jin Young Kim; Suyon Chang; Hye-Jeong Lee; Jin Hur; Young Jin Kim; Byoung Wook Choi
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

9.  Characterization of myocardial T1-mapping bias caused by intramyocardial fat in inversion recovery and saturation recovery techniques.

Authors:  Peter Kellman; W Patricia Bandettini; Christine Mancini; Sophia Hammer-Hansen; Michael S Hansen; Andrew E Arai
Journal:  J Cardiovasc Magn Reson       Date:  2015-05-10       Impact factor: 5.364

10.  Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping.

Authors:  Heerajnarain Bulluck; Matthew Hammond-Haley; Marianna Fontana; Daniel S Knight; Alex Sirker; Anna S Herrey; Charlotte Manisty; Peter Kellman; James C Moon; Derek J Hausenloy
Journal:  J Cardiovasc Magn Reson       Date:  2017-08-01       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.